ArticleBMC research notes2025
Isolation and characterization of ɸEcM-vB1 bacteriophage targeting multidrug-resistant Escherichia coli.
Article in BMC research notes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Genomic and phenotypic characterization of Klebsiella pneumoniae phage KP Ø1: a novel lytic Slopekvirus targeting uropathogenic multidrug-resistant Klebsiella pneumoniae.Scientific reports · 2026Article
- Isolation and therapeutic potential of phage vB_EcoM_GXW16 against a drug-resistant avian pathogenic Escherichia coli strain.Poultry science · 2026Article
- Phenotypic and Genomic Characterization of Novel Straboviridae Bacteriophages Targeting Multidrug-ResistantMicroorganisms · 2026Article
- A comprehensive analysis of the kinetics of infection of lytic bacteriophages specific to the ESKAPE and critical pathogens.World journal of microbiology & biotechnology · 2026Review
- Isolation and Characterization of a Novel Thermostable Bacteriophage Targeting Multi-Drug-ResistantViruses · 2025Article
- Isolation and Genomic Analysis ofAntibiotics (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThe aim of this study is to screen for, isolate and characterize a bacteriophage designated ɸEcM-vB1 with confirmed lytic activity against multidrug-resistant (MDR) E. coli. Methods done in this research are bacteriophage isolation, purification, titer determination, bacteriophage morphology, host range determination, bacteriophage latent period and burst size determination, genomic analysis by restriction enzymes, and bacteriophage total protein content determination.
resultsɸEcM-vB1 bacteriophage exhibited high lytic activity against different MDR E. coli isolates and showed stability over wide pH and temperature range. It belongs to the Myoviridae family of the caudovirales order according to TEM. It had a latent period of 5 min and an average burst size of 271.72 pfu/cell. Genomic analysis revealed that it is susceptible to digestion by EcoRI. Ten structural proteins were detected by SDS-PAGE. ɸEcM-vB1 is considered a promising candidate for phage therapy applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.